X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs SUN PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH SUN PHARMA PANACEA BIOTECH/
SUN PHARMA
 
P/E (TTM) x -16.0 43.3 - View Chart
P/BV x 1.9 3.4 56.3% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 PANACEA BIOTECH   SUN PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
SUN PHARMA
Mar-18
PANACEA BIOTECH/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs149701 21.2%   
Low Rs82433 19.0%   
Sales per share (Unadj.) Rs84.1110.4 76.2%  
Earnings per share (Unadj.) Rs-18.311.0 -166.8%  
Cash flow per share (Unadj.) Rs-6.717.2 -38.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs83.7158.8 52.7%  
Shares outstanding (eoy) m61.252,399.26 2.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.45.1 26.7%   
Avg P/E ratio x-6.351.6 -12.2%  
P/CF ratio (eoy) x-17.232.9 -52.4%  
Price / Book Value ratio x1.43.6 38.7%  
Dividend payout %018.2 0.0%   
Avg Mkt Cap Rs m7,0741,360,021 0.5%   
No. of employees `0002.817.8 15.5%   
Total wages/salary Rs m1,44953,671 2.7%   
Avg. sales/employee Rs Th1,874.114,890.9 12.6%   
Avg. wages/employee Rs Th527.03,017.1 17.5%   
Avg. net profit/employee Rs Th-407.71,480.6 -27.5%   
INCOME DATA
Net Sales Rs m5,154264,895 1.9%  
Other income Rs m1008,388 1.2%   
Total revenues Rs m5,254273,282 1.9%   
Gross profit Rs m-76656,081 -1.4%  
Depreciation Rs m71114,998 4.7%   
Interest Rs m1,5035,176 29.0%   
Profit before tax Rs m-2,88144,295 -6.5%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771-9,505 -18.6%   
Tax Rs m178,452 0.2%   
Profit after tax Rs m-1,12126,338 -4.3%  
Gross profit margin %-14.921.2 -70.2%  
Effective tax rate %-0.619.1 -3.1%   
Net profit margin %-21.89.9 -218.8%  
BALANCE SHEET DATA
Current assets Rs m3,810316,359 1.2%   
Current liabilities Rs m8,365198,643 4.2%   
Net working cap to sales %-88.444.4 -198.9%  
Current ratio x0.51.6 28.6%  
Inventory Days Days15695 164.2%  
Debtors Days Days67108 62.4%  
Net fixed assets Rs m14,480213,178 6.8%   
Share capital Rs m612,399 2.6%   
"Free" reserves Rs m903378,606 0.2%   
Net worth Rs m5,127381,006 1.3%   
Long term debt Rs m5,83217,721 32.9%   
Total assets Rs m19,433643,028 3.0%  
Interest coverage x-0.99.6 -9.6%   
Debt to equity ratio x1.10 2,445.5%  
Sales to assets ratio x0.30.4 64.4%   
Return on assets %2.04.9 40.1%  
Return on equity %-21.96.9 -316.4%  
Return on capital %3.610.0 36.3%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,53940,816 3.8%   
Fx outflow Rs m94230,143 3.1%   
Net fx Rs m59710,673 5.6%   
CASH FLOW
From Operations Rs m59939,072 1.5%  
From Investments Rs m-438-33,708 1.3%  
From Financial Activity Rs m-303-15,393 2.0%  
Net Cashflow Rs m-141-7,359 1.9%  

Share Holding

Indian Promoters % 74.5 63.7 117.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 5.1 11.7%  
FIIs % 1.3 23.0 5.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 8.3 284.3%  
Shareholders   10,259 133,026 7.7%  
Pledged promoter(s) holding % 35.1 0.5 6,617.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Nov 21, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS